LS-125-2D4-11-10-1 [2D4] (ATCC® HB-12644)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte  / 

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Age adult
Strain

Strain:  BALB/c (B cell); BALB/c (myeloma)

Applications
The antibody binds to the human CC-chemokine receptor 1 (CCR1).
Storage Conditions liquid nitrogen vapor phase
Images
Derivation
Animals were immunized with the murine pre-B cell line L1-2 expressing high levels of transfected human CCR1. Spleen cells were fused with Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 1 (CCR1).
Comments
Animals were immunized with the murine pre-B cell line L1-2 expressing high levels of transfected human CCR1. Spleen cells were fused with Sp2/0 myeloma cells. The antibody binds to the human CC-chemokine receptor 1 (CCR1).
Complete Growth Medium Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 1 ng/ml Interleukin-6 (IL-6), 90%; fetal bovine serum, 10%
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml.
Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype IgG1 kappa
Name of Depositor Millennium Pharmaceuticals, Inc.
References

Qin S, et al. Anti-CCR1 antibodies and methods of use therefor . US Patent 6,329,510 dated Dec 11 2001

Basic Documentation
Other Documentation
References

Qin S, et al. Anti-CCR1 antibodies and methods of use therefor . US Patent 6,329,510 dated Dec 11 2001